Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Barngrover

Interventional Pain Medicine Columbus, GA Doctor of Osteopathy

NPI 1588787162 CMS profile 117126

5669 Whitesville Rd, Columbus, GA 31904

Open in the dashboard

General payments

$11,749

522 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Barngrover of Columbus, GA is reported in the CMS Open Payments database as having received $11,749 across 522 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,392 72
2024 General $1,271 97
2023 General $1,731 97
2022 General $4,121 78
2021 General $1,482 71
2020 General $744 45
2019 General $1,008 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Barngrover
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Kenneth Barngrover were reported at $1,392. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Kenneth Barngrover Interventional Pain Medicine median Middle half National median
2019 $1,008 $684 $216–$2,079 $163
2020 $744 $382 $122–$1,109 $114
2021 $1,482 $552 $167–$1,554 $132
2022 $4,121 $605 $187–$1,924 $149
2023 $1,731 $671 $195–$1,915 $160
2024 $1,271 $684 $206–$1,837 $164
2025 $1,392 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,657 106 payments
  2. Collegium Pharmaceutical, Inc. $1,556 99 payments
  3. Merz North America, Inc. $1,519 16 payments
  4. Boston Scientific Corporation $928 45 payments
  5. Scilex Pharmaceuticals Inc. $831 50 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $734 42 payments
  7. Pfizer Inc. $401 27 payments
  8. Eisai Inc. $356 21 payments
  9. Merck Sharp & Dohme Corporation $213 15 payments
  10. Biodelivery Sciences International, Inc. $208 18 payments
  11. Other $1,346 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,281 517 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 1 payment
  3. Education $68 4 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $3,288 85 payments
  2. XTAMPZA $1,226 76 payments
  3. Xeomin $1,146 11 payments
  4. WaveWriter Alpha Prime 16 $824 37 payments
  5. QULIPTA $712 57 payments
  6. RELISTOR $636 36 payments
  7. ZTLido $607 35 payments
  8. Dayvigo $356 21 payments
  9. NURTEC ODT $338 22 payments
  10. BELBUCA $330 23 payments
  11. Other $3,368 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

14,844

Median for Pain Management: 951

Drug cost

$949,768

Median for Pain Management: $26,034

Branded share of claims

53.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Percocet Oxycodone Hcl/Acetaminophen Brand 23 $120,614
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 3,117 $110,826
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 3,289 $102,718
Xtampza Er Oxycodone Myristate Brand 127 $88,311
Oxycontin Oxycodone Hcl Brand 109 $84,402
Belbuca Buprenorphine Hcl Brand 101 $74,765
Buprenorphine Generic 149 $51,641
Ztlido Lidocaine Brand 36 $38,893
Nurtec Odt Rimegepant Sulfate Brand 21 $36,087
Morphine Sulfate Er Morphine Sulfate Brand 810 $32,347

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$383,678

Of which drugs: $17,714

Medicare patients

345

Average age 68

Services billed

8,267

212 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Depression 34%
Chronic kidney disease 28%
COPD 26%
Ischemic heart disease 25%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 42 130 $559
Injection, methylprednisolone acetate, 1 mg J1010 Office 102 1,603 $153

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $387
$387 127 —
ZTLido
  • Scilex Pharmaceuticals Inc. $143
$143 36 —
UBRELVY
  • AbbVie, Inc. $129
$129 20 —
QULIPTA
  • AbbVie, Inc. $118
$118 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

522 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record